References
- Santos-Gallego CG, Badimon JJ, Rosenson RS. Beginning to understand high-density lipoproteins. Endocrinol Metab Clin N Am. 2014;43:913e947.
- Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.
- Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:3–46.
- Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014;384:618–625.
- Kakafika A, Athyros VG, Tziomalos K, et al. High density lipoprotein cholesterol and statin trials. Curr Med Chem. 2008;15:2265–2270.
- Bermudez V, Cano R, Cano C, et al. Pharmacologic management of isolated low high-density lipoprotein syndrome. Am J Ther. 2008;15:377–388.
- Forey BA, Fry JS, Lee PN, et al. The effect of quitting smoking on HDL-cholesterol - a review based on within-subject changes. Biomark Res. 2013;1:26.
- Boey E, Gay GM, Poh KK, et al. Visit-to-visit variability in LDL- and HDL-cholesterol is associated with adverse events after ST-segment elevation myocardial infarction: A 5-year follow-up study. Atherosclerosis. 2016;244:86–92.
- Ballocca F, Gili S, D’Ascenzo F, et al. HIV infection and primary prevention of cardiovascular disease: lights and shadows in the HAART Era. Prog Cardiovasc Dis. 2016;pii: S0033-0620(16)30017–2. doi:https://doi.org/10.1016/j.pcad.2016.02.008.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [ updated: Jan 28, 2016; cited 2016 May 5]. Available from. http://aidsinfo.nih.gov/guidelines
- Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA panel. JAMA. 2014;312:410–425.
- General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014;81:14–18.
- Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2935–2959.
- Okeke NL, Davy T, Eron JJ, et al. Hypertension among HIV-infected Patients in Clinical Care, 1996–2013. Clin Infect Dis. 2016;63:242–248. doi:https://doi.org/10.1093/cid/ciw223.
- Fernández-Montero JV, Barreiro P, de Mendoza C, et al. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral Hepat. 2016;23:47–52.
- Alexander KS, Kazmierczak SC, Snyder CK, et al. Prognostic utility of biochemical markers of cardiovascular risk: impact of biological variability. Clin Chem Lab Med. 2013;51:1875–1882.
- Veloudi P, Blizzard CL, Head GA, et al. Blood pressure variability and prediction of target organ damage in patients with uncomplicated hypertension. Am J Hypertens. 2016;pii: hpw037. DOI:https://doi.org/10.1093/ajh/hpw037
- Whittle J, Lynch AI, Tanner RM, et al. Visit-to-visit variability of BP and CKD outcomes: results from the ALLHAT. Clin J Am Soc Nephrol. 2016;11:471–480.